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Abstract: Atopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of
the skin, categorized by robust burning and eczematous lacerations in diverse portions of the
body. AD affects about 20% of both offspring and adults worldwide. The pathophysiology of
AD combines environmental, hereditary, and immunological aspects, together with skin barrier
dysfunction. The procedures used to prevent the disease are the everyday usage of creams to
support the restoration of the epidermal barrier. The classical treatments include the use of topical
corticosteroids as a first-line therapy, but also calcineurin inhibitors, antihistamines, antibiotics,
phototherapy, and also immunosuppressant drugs in severe cases of AD. Topical drug delivery to
deeper skin layers is a difficult task due to the skin anatomic barrier, which limits deeper penetration
of drugs. Groundbreaking drug delivery systems, based on nanoparticles (NPs), have received much
attention due to their ability to improve solubility, bioavailability, diffusion, targeting to specific types
of cells, and limiting the secondary effects of the drugs employed in the treatment of AD. Even so,
additional studies are still required to recognize the toxicological characteristics and long-term safety
of NPs. This review discusses the current classical pharmacotherapy of AD against new nanoparticle
skin delivery systems and their toxicologic risks.
Keywords: atopic dermatitis; drug delivery systems; pharmacological treatment; nanotechnology;
nanoparticles
1. Introduction
Atopic dermatitis (AD) is a chronic skin illness characterized by itchy, reddish, and scaly lesions
along with a continuous inflammatory pattern [1]. AD arises commonly in familial context with
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a prevalence of atopic conditions, as allergic rhinitis or bronchial asthma, and food allergies [2].
Topical administration of drugs is still the main therapeutic approach for AD. Despite this, several
disadvantages may be cited as reduced patient compliance (a consequence of adverse effects as skin
irritation or allergy), low efficiency, and specificity of these systems in delivering therapeutic drugs [3].
Innovative drug delivery systems should, therefore, exhibit the capacity to penetrate the stratum
corneum (SC), which is naturally impermeable to a range of substances, in order to reduce adverse effects
and increase drug targeting [3–5]. There is still no medication capable of reversing the pathological
effects of AD. However, formulations based on nanoparticles (NPs) have been exploited for topical
administration of drugs and are expected to overcome the above-mentioned limitations [6–8].
2. Pathophysiology
AD, also called atopic eczema, is the most common skin disease, characterized by a pattern of
pruritus, skin deterioration, and chronic inflammation [1,6,7]. This illness affects individuals in early-,
mid- or late-stages of their lives and does not have a known cure so far. Over the course of the disease,
the levels of IgE increase drastically leading to cutaneous signals that appear in early ages and persist
until late stages of life, when they begin to disappear. Because of this, AD is also labelled as “allergic
march” [2].
AD results from a multiplicity of factors such as environmental injuries, impairments against
the natural barrier of the skin and response of the immune system. This latter enhances the activity
of mast cells and T-lymphocytes, followed by higher levels of IgE in patients serum, inflammatory
signals, and pruritus [9–11]. Very common features amongst AD patients are pruritus, papules related
to erythematous pruritic lesions, xerosis, skin rashes, and serous exudate as the result of the persistent
inflammation [2,12]. The eyelid often presents a second fold in the skin, known as Dennie-Morgan
fold [9,11,12]. Two theories are advanced to clarify the skin disruption and appearance of cutaneous
lesions/skin rash. The first, named “in-out”, is based on an imperfect skin barrier. The second, called
“inside-out”, originated from the concept of the adaptive immune system burden. The first theory
is more recent, and its foundations concern the vital role of skin impairment in the immune system
activation. The two theories are not self-excluded, but are complementary [13–15].
2.1. Skin Barrier
The normal function of the skin is regulated primarily by both physical and chemical integrity of
this barrier, limiting both the loss of water, and the entrance of pathogens and immunogenic molecules.
In this way, it avoids the contact of such molecules with antigen-presenting cells, and thereby, limits the
response of the immune system [11,16]. When the skin barrier functions fail, the risk of proliferation of
microorganisms and of invasion of antigens increases [2,15].
The mechanisms allowing the disruption of this barrier are based on three main changes in
skin homeostasis, namely, (i) alterations in lipid composition and secretion, (ii) fluctuations in the
differentiation processes of the epidermal terminal, and (iii) mutations in the gene coding filaggrin
(filament-aggregating protein), due to its role in the synthesis of natural hydration factor (which
upholds keratinocytes linked) and in the differentiation of epidermal terminal. Missense or nonsense
mutations lead to altered or even a loss of function of the gene. In the case of mutations in the filaggrin
gene, these are related to the enhanced risk of developing AD. These effects are the result of higher
skin pH, triggering phenomena, such as serine proteases, increased synthesis of cytokines, and the
development of Staphylococcus aureus (S. aureus) with parallel colonization of microbes. The higher the
density of these pathogens in the skin, the higher the seriousness in the clinical setting of AD [11,14,16].
Skin homeostasis is regulated by a myriad of factors that govern the capacity of skin cells to
divide, proliferate, and differentiate. Sphingolipids (SPL) are a class of molecules that interfere in the
processes of cell regulation with functions at the structural and biological levels [17]. AD is currently
associated with SPL and ceramides (CR) impairment at the epidermal level (namely in the SC), when
compared to the skin of aged patients. The lack of SPL and CR is a key factor in the development of
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dehydrated and disrupted skin. The physiological concentration of ceramides in the SC is regulated
by three vital enzymes, β-glucocerebrosidase, sphingomyelinase, and ceramidase, whose function is
to hydrolyze the former [18]. In the case of AD patients, a de novo enzyme was identified, named
sphingomyelin/glucosylceramide deacetylase, which catalyzes the hydrolysis of glucosylceramide or
sphingomyelin at the level of the acyl group. In these patients, it has an activity increased five-fold
when compared to normal individuals [19]. This massive increase explains the reduced levels of both
CR and sphingosine. The decrease of these two molecules is also connected to a reduced transepidermal
water loss and the faint levels of sphingosine are related to the risk of bacterial infections. Studies
on skin dysfunction in AD demonstrated the loss in the synthesis of ceramides, which is essential
for healthy skin. The biosynthesis of ceramides differs among ethnic groups, and there is still no
connection between the filaggrin gene and ceramide synthesis [19,20]. A study, performed using SPL
extracts, demonstrated the potential positive impact in the production of ceramides, which leads to an
ordered SC and an improvement in AD status [21]. Another study, this time using a cream composed
of ceramides and magnesium, demonstrated higher benefits in the skin over other methods, such
as corticosteroids (which modify skin moisturizing factors) or even lipid-enriched emollients [22].
Current efforts are being driven to scrutinize the pathophysiology of AD and to yield molecular targets
for future pharmacological treatments.
2.2. Skin Immunology
Skin immunology suggests the existence of a discrepancy amongst the action of innate and
adaptive immune systems, triggering an irregular reply of T-cells. The result is an increase in the
synthesis of interleukins (IL-4, IL-5, IL-13), which hinder the differentiation of the Th1-cells, as well as
increase the synthesis of IgE, which elevate the levels present in about half of the occurrences [8,12].
3. Epidemiology
Epidemiological data point to about 20% of probability of an individual to develop AD during its
lifetime. The prevalence of the disease is about 15–30% both, in children and in adults [23]. While, the
total prevalence of AD depends on the country/region, a marked increase has been noted between 1950
and 2000, a phenomenon termed “allergic epidemy” [12], with the highest incidence in industrialised
countries [23]. AD develops in 95% of the cases in children aged under five-years-old [12], but overall,
60% of the AD cases are reported in children under one-year old [11]. Nevertheless, AD likewise
disturbs adults, accounting for 1% to 3% of prevalence [24].
4. Clinical Diagnosis
AD is currently diagnosed via clinical observation. This procedure is still needed due to the
lack of specific and validated laboratory assays to rapidly determine the presence or absence of the
illness [25]. When clinical observations are questionable, skin biopsies are often performed to clear-cut
other pathologies, as T-cell lymphoma, which trigger the same signals and symptoms [26,27]. Briefly,
the combination of an exact anamnesis and an appropriate physical examination are crucial for an
improved diagnosis. Physicians should be focused on the distribution and morphology of the lesions
and relate them to the age of the patient [2]. Other features that are considered critical in the diagnostic
process are the presence of ichthyosis vulgaris, pruritus, xerosis, and relapsing eczematous lesions [9].
The injuries identified according to the symptomatology are: Allergic contact eczema, irritant eczema,
toxic contact eczema, infective eczema, and nummular eczema. Middle-aged patients show symptoms
that may resemble AD as eczematous rashes derived from pathological conditions, such as scabies,
erythroderma, psoriasis, seborrheic dermatitis, cutaneous T-cell lymphoma, and immune deficiency
syndromes. In such circumstances, a differential set of diagnostic tests is mandatory [28].
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5. Prevention
To avoid AD three strategies are considered. The first relates to the exclusion of food-derived
allergens. The second concerns the reduction, as much as possible, of the contact with antigen
sources from pollens, mite dust, traffic or tobacco smoke, volatile organic compounds, and animal
fur [29–31]. The third combines these two strategies plus the employment of daily skin emollients and
lotions [2,31,32]. So far, it has been noted that using skin emollients on daily regimens decreases the
risk of children developing AD by 30% to 50% [33,34].
6. Non-Pharmacological and Pharmacological Treatments
AD treatments have four main aims, namely; improving patients’ quality of life, reducing the
severity of the pathology, preventing further infections and controlling the illness in the long-term [11,35].
Table 1 provides an overview of the current therapeutic approaches in AD. Presently used therapeutic
approaches recommend skin hydration, skin inflammation control, and renewal of skin structure by
application of emollients [6,7,26]. The use of moisturizers to soften AD-diseased skin is one of the
principal treatment approaches. Pharmacological approaches consist of the use of topical corticosteroids
to reduce inflammation, antibiotics (namely antimicrobials) to eradicate infections induced by bacteria
or other parasites, antihistamines to reduce pruritic symptoms, and calcineurin inhibitors to prevent
eczema propagation and to reduce inflammation as well. Phototherapy and immunomodulation by
systemic administration of immunosuppressant drugs are also proposed [25,36].
Table 1. Overview of the current therapeutic approaches in Atopic Dermatitis (AD).
Antihistamines Diphenhydramine Hydroxyzine
Anti-microbials Systemic antibiotics (e.g., cyclosporine)Topical antibiotics (e.g., gentamicin, fusidic acid, mupirocine)
Corticosteroids
Systemic corticosteroids (e.g., prednisolone)
Topical corticosteroids (e.g., hydrocortisone, fluticasone,
betamethasone)
Education
Advantages of treatment compliance
Application of topical therapy
Nature of the disease
Phototherapy UVB lightUVA light
Skincare
Moisturizers
Daily skincare
Emollients
Regular bathing
Systemic immunosuppressant drugs
Azathioprine
Ciclosporin
Methotrexate
Mycophenolate mofetil
Topical calcineurin inhibitors PimecrolimusTacrolimus
6.1. Non-Pharmacological Approaches
6.1.1. Moisturizers
The composition of a skin moisturizer is complex and consists of using emollients, humectants, and
occlusive agents. Commonly used Humectants, include glycerol, urea, or lactic acid; amongst the most
frequent included emollients are glycol stearate, glyceryl stearate, and soy-derived sterols; while the
occlusive agents include petrolatum, dimethicone, and mineral oils [28], as well as nanoparticles [37].
The choice of the emollient depends on the distinct characteristics of the skin of each patient. Emollients
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applied topically are commonly employed in dry and lichenified skin, and should ensure extensive skin
lubrication [35]. To prevent skin water loss, occlusive agents are used due to their ability to generate
an occlusive coating. Humectants also improve the hydration of skin but, instead of generating an
occlusive layer, they retain the water molecules via penetration through the skin (oppositely to occlusive
agents that do not permeate across the skin) and promote SC hydration [10]. Daily moisturizers
should not have scents or perfumes in their composition as these are potential allergens that can cause
further dysfunction of the already diseased skin. Despite the currently available pool of data from the
literature, there is still no evidence that emollients, composed of ceramides and fatty acids, are better
than old-style emollients [25,35]. Emollients should, therefore, be considered in the primary care of
AD [38].
6.1.2. Bath and Wet Wraps
A daily bath is a mandatory habit in the life of an AD patient. It is intended to remove allergens,
skin scales, and irritant substances accumulated every day on the surface of the skin [32]. The use of
wat wraps reduces skin water loss, avoiding dry skin and further cutaneous rash and itching. The
procedure should be performed as follows: Firstly, the patient must take a bath and, afterwards, apply
corticosteroids or emollients directly on the skin; the treated skin regions are then wrapped using
wet bandages and, only after that, the normal dry outfit. Topical application of corticosteroids has
increased benefits when simultaneously used of wet wraps due to increased drug absorption [11,32].
6.2. Pharmacological Approaches
6.2.1. Topical Corticosteroids
The primary treatment of AD includes topical corticosteroids. In children, this class of molecules
must be carefully chosen, and only low-potency corticosteroids should be used. An exception to this
rule applies only when low-potency corticosteroids do not present effective results. High-potency
corticosteroids are, therefore, employed to avoid severe scenarios [35]. The management of this
class of drugs must be understood by users and caretakers in order to minimize adverse effects
(e.g., skin receding or skin stretch marks), which may result in low patients’ compliance due to
corticophobia [25,33]. The physician’s recommendations and dose tunings are vital to expanding the
success of corticotherapy [11].
6.2.2. Antibiotic Treatments
Antibiotics are recommended in patients infected by S. aureus to prevent spreading of the
microorganisms which, otherwise, infects other patients. Administration can be oral or intravenous.
In cases of severe AD, the patients infected with S. aureus may undergo antibiotic therapy, aiding in the
withdrawal of bacterial clusters and, thus, improving the clinical state of the patients. Despite this, the
topical application of antibiotics is not yet proven to be advantageous in the treatment of concomitant
infection with S. aureus in AD patients [32,35]. Nevertheless, the choice of the antimicrobial drug is of
topmost importance in circumventing the resistance effects of the microorganisms [11].
6.3. Antihistamines
Pruritus is the most influential symptom of the disease affecting the life quality of these patients [11].
Antihistamines are commonly used to decrease the overall itching. However, these drugs are not
used for the effective treatment of eczema, but for ameliorating the symptoms [25]. Scientific data
are somehow contradictory, i.e., some describe no superiority of antihistamines when compared to
placebo. Whereas, others show an antipruritic outcome [39,40]. An adverse effect of first-generation
antihistamines is related to their capacity to sedate, which can be profitably used in AD patients that
have a frequent disturbance of sleep [39,40].
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6.3.1. Calcineurin Inhibitors
Calcineurin inhibitors are classified as anti-inflammatory agents of non-steroidal origin. They
exhibit their actions through blockage of activated T-cells cytokine transcription, leading to a decline
in the inflammation degree [41]. The application of these drugs in the affected areas of the skin
improves the condition without triggering skin shrivelling [35]. Calcineurin inhibitors are a second-line
choice in short-term treatments. The simultaneous use of emollients and calcineurin inhibitors is
strongly recommended. Nevertheless, the formulations must be applied at distinct time points to
prevent a dilution result. Other cases of success are the topical use of immuno-modulators, namely
pimecrolimus as a cream with mild-corticosteroid properties, and tacrolimus as a cream with moderate-
to strong-corticosteroids properties. Both cases were shown to decrease excoriations, pruritus, and
erythema [42].
6.3.2. Phototherapy
The incidence of ultraviolet radiations—ultraviolet A (UVA) and ultraviolet B (UVB) - leads to
cellular damages. Studies performed with UVB demonstrated its potential to reduce bacteria onto the
skin, as well as the synthesis of superantigen by S. aureus [43]. A therapeutic approach for AD-derived
eczema might consist of applying UVA and UVB together with topical corticosteroids. Despite this, the
UVA and UVB radiations contribute to accelerating skin ageing and increased risk of skin cancer [44,45].
6.3.3. Systemic Immunosuppressant Drugs
In life-threatening cases of AD, as when classical treatments like the topical administration
of corticosteroids and phototherapy have lost their efficacy, methotrexate, mycophenolate mofetil,
and azathioprine substances, belonging to the class of systemic immunosuppressant drugs, are the
alternative approach [35]. Emollients must be used in parallel to re-establish the water-lipid film of the
skin [11].
7. Nanotechnology for Topical Applications
Nanoparticles (NPs) stand for materials with dimensions less than 100 nm [46,47], and have been
proposed for the topical delivery of drugs aimed at treating skin diseases [32]. NPs may contribute to
reduce adverse effects of classical drugs (e.g., topical corticosteroids), as the former show improved
safety profile as less drug is needed due to the site specific delivery. NPs have also been proposed as a
preferential approach to poor drug solubility and limited skin permeability, thereby increasing skin
bioavailability [48,49]. Several types of nanoparticles have been proposed for the topical delivery of a
set of different drugs useful in AD, e.g., antibiotics and corticosteroids [7,8]. A schematic representation
of types of nanoparticles used in topical delivery of drugs is shown in Figure 1.
NPs offer opportunities to improving drug penetration through the SC, increase the retention time
of drugs, and design better profiles of drug release to reach therapeutic goals. NP-based formulations
may, therefore, be an improved approach over traditional drug formulations. One of the most
relevant advantages of NPs is the potential reduction of serious adverse effects related to poor patient
compliance and, thus, reduced therapeutic outcomes [3,50]. Among the different NPs, those composed
of lipid materials have shown superior advantages attributed to the compatibility with the lipid skin
composition [48,51–54].
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7.1. Vesicular Systems
7.1.1. Liposomes
Liposomes are formed by ordinary phospholipids found in living systems that are disposed
in concentric bilayers. This display generates a hydrophilic environment in the core of the vesicles
and a lipophilic environment between the layers of phospholipids. Cholesterol is employed in the
manufacturing of liposomes to avoid phospholipid aggregation and to allow membrane fluidity.
Liposomes are versatile structures showing interesting characteristics as biocompatibility, increased
ability to penetrate and permeate across the epidermis (feature derived from the lipid-similarity to
this biological structure), and the possibility to encapsulate both lipophilic and hydrophilic molecules.
These properties make liposomes a very reliable source of drug carriers [3,4,32].
7.1.2. Transfersomes
Transfersomes show many structural similarities with liposomes but exhibit higher flexibility in
penetrating through the SC via intracellular and/or intercellular routes. They can also pass through
pores smaller than their diameter because of their flexibility, a feature attributed to their amphipathic
assembly containing a surfactant [55].
7.1.3. Ethosomes
Ethosomes are also structurally similar to liposomes. Due to their higher flexibility they are also
called elastic vesicles. Ethosomes are classified into three distinct categories: classical ethosomes, binary
ethosomes and transethosomes. The composition of classical ethosomes is based on phospholipids,
highly concentrated ethanol, and water. Binary ethosomes have an identical composition to classical
ethosomes but replacing the alcohol by propylene glycol or isopropyl alcohol. Transethosomes are also
identical to classical ethosomes with the exception of the additional surfactant that allows flexibility of
vesicles and penetration across pores smaller than their sizes [56–58]. Ethosomes-derived formulations
together with transfersomes can cross pores smaller than their diameter due to the high fluidity of the
lipidic membrane. Ethosomes were experimentally shown to efficiently deliver targeted drugs in a
higher extent than liposomes, and other solutions based on ethanol and water [3,59,60].
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7.1.4. Proliposomes
Proliposomes are vesicular carriers forming liposomes after entropy-driven reconfiguration. They
show a trend towards aggregation due to the lack of water molecules, which contribute to protein
stability. Once the shell of the vesicular carrier is hydrated the drug is released with parallel rise of
skin permeation. As these structures are easily scaled-up to meet industrial processing requirements,
they have become an interesting method to deliver therapeutic molecules [61].
7.1.5. Cubosomes
Cubosomes were developed to encapsulate peptide- and protein-derivative drugs given their
ability to prevent enzymatic modifications. They are generated by emulsifying a lipid phase with
cubic geometry in water yielding NPs in liquid state with crystalline properties. Given their structure,
lipophilic drugs can be encapsulated by incorporation in the lipid bilayers, and hydrophilic drugs
can be encapsulated within the aqueous channels in the structure of the vesicles. Amphipathic drugs,
on the other hand, are placed between the lipid bilayer and the water phase. These vesicles have
optimized parameters as low viscosity, increased stability to elevated temperatures, and a higher
surface area. The drug-releasing mechanism govern the percutaneous absorption of drugs [3,62–64].
7.2. Nanoparticles
7.2.1. Lipid Nanoparticles
Lipid nanoparticles refer to solid lipid nanoparticles (SLN) and nanostructured lipid carriers
(NLC), both among the range of NPs of interest for skin drug delivery [48,49,65,66]. SLN are mainly
composed of solid lipids. Whereas, NLC are composed of a blend of solid and liquid lipids; both SLN
and NLC matrices remain solid at body and room temperatures. Both lipophilic and hydrophilic drugs
are prone to be encapsulated in SLN, while, NLC are specifically tailored to load lipophilic drugs. SLN
and NLC improve drug permeation through the SC and retain them both in epidermis and dermis.
SLN and NLC can also re-establish the health of the skin as they reduce the transepidermal water loss,
a property linked to the adhesiveness of the particles and to their minor size, yielding occlusion of the
skin and, therefore, preventing water evaporation [37,67].
7.2.2. Polymeric and Polysaccharide Nanoparticles
Polymeric nanoparticles commonly employ polylactic acid (PLA), poly(ε-caprolactone) or
poly(lactic-co-glycolic acid) (PLGA) [68–73], whereas polysaccharide nanoparticles are based on,
e.g., chitosan [74], alginate [75,76], all non-toxic, biocompatible, and biodegradable polymers.
7.2.3. Dendritic Nanoparticles
Dendritic NPs allow the conjugation of a diversity of molecules in their shells. Amongst those
characteristics is the flexibility permitted by the macromolecules constituting these systems, the small
polydispersity index, as well as the hyperbranched lattice with a regular stride [77,78].
7.3. Nanoemulsions
Nanoemulsions are isotropic binary systems, composed of two immiscible liquids, forming oil
droplets of nanometer size dispersed in aqueous phase and stabilized by at least one surfactant. Unlike
microemulsions, nanoemulsions are thermodynamically unstable, showing higher capacity to load
lipophilic drugs. In biological systems, they have the ability to penetrate through healthy or diseased
skin. Nanoemulsions also have the potential to increase the bioavailability of drugs. This phenomenon
is derived from their positive charge, which is attracted by the negatively charged corneocytes, present
in the SC leading to enhanced percutaneous drug absorption [51,53,79–81].
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8. Production of Nanoparticles Delivery Systems
For the production of nanoparticles, two strategies are described, namely top-down or bottom-up
(Figure 2).Int. J. Mol. Sci. 2019, 20, x 9 of 17 
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Figure 2. Top-down and bottom-up strategies for the production of nanoparticles.
8.1. Top-Down
Top-down approaches are based on the reduction of macroparticles until these reach the nanometric
scale. To accomplish so, a variety of methods are available as lithography, which includes derived
methods, such as nanoimprinting, electron-beam, nanostencil, photonic, interference, nanospheres,
high-pressure homogenization, including homogenization (e.g., microfluidization, piston-gap) and
milling. One of the main advantages of top-down approaches is the preservation of the crystalline
structure of the NPs. Although, this is the main common outcome, the development of an amorphous
structure does often occur throughout the process of milling. To promote recrystallization, a solvent is
frequently used to obtain pure drug NPs. Regarding the method of microfluidization, a critical factor
to ensuring the reduction of the particle size is the presence of a jet of air, which acts as a milling system
by promoting the impact between particles. A disadvantage of top-down approaches is the need for
high input of energy, which is often expensive [82,83].
8.2. Bottom-Up
Whilst top-down approaches are based on the reduction of materials to achieve a proper
formulation, bottom-up methodologi s start with smaller building-blocks and assemble them in
bigger structures. A ong th se, self-assembly, precipitation, or emulsification of starting-materials are
commonly applied. From a practical perspective, this is re ched by setting a drug or a mix of drugs into
solution. Then, using procedures that precipitate or crystalize the drugs in solution, NPs are built up.
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The last step consists of evaporating the solvent to yield the desired constructs. A strong advantage of
these methodologies is the minor amount of energy needed along with small economical expenditures.
Nonetheless, the techniques are prone to yield both crystalline and amorphous structures of NPs, and
associated irregularities in parameters, such as shape, size of the NPs, and the respective polydispersity
index [82,83].
9. Nanoparticles and Skin Penetration
The penetration of the NPs applied topically is done by at least one of three routes, i.e., intracellular
route, intercellular route or through hair follicles and sweat glands. Critical governing parameters
the NPs permeability through the skin are their size, the type of surfactant surrounding the particles
and their surface electrical charge (i.e., zeta potential). If NPs have a mean diameter not superior to 4
nm, they can easily penetrate or permeate through the intact skin; if the diameter is between 4 and
20 nm, NPs can permeate via damaged or intact skin; if the diameter of the NPs is under 45 nm they
can be permeated or penetrate insalubrious skin. For sizes greater than 45 nm, NPs, susceptible to
be accumulated or translocated in, or through, skin appendices, proved difficult in penetrating and
permeating the skin [84].
The loading of drugs into NPs can potentially improve their physicochemical stability, their
bioavailability, and reduce their adverse side effects [2]. NPs can also reduce the overall tissue capacity
of clearance, and thereby, increase the drug concentration in the diseased tissue. Due to the controlled
release profile of the entrapped drug and the high surface area, NPs are an interesting approach for
site-specific drug delivery to the skin [29,30,47]. Negatively charged NPs can interact with positively
charged keratinocytes, thereby, enhancing the NPs retention onto the skin and extended drug release.
10. Nanoparticles for Atopic Dermatitis
Chitosan NPs, containing betamethasone valerate, were produced and coated with hyaluronic
acid to improve the pharmacological effects of the drug and the capacity for targeted delivery [85].
NPs displayed a Fickian diffusion release profile in simulated skin, with enhanced drug permeation in
comparison to the non-loaded drug. Coating the particles with hyaluronic acid better improved drug
retention in the epidermis and the dermis.
Siddique et al. loaded hydrocortisone and hydroxytyrosol—a glucocorticoid for topical application,
and an antioxidant molecule, respectively, in chitosan NPs, which were then formulated in an aqueous
cream [86]. The authors reported no systemic effects of the drugs nor toxicity, with enhanced safety and
tolerability of the developed cream. Chitosan NPs loading hydrocortisone showed their capacity to
reduce the erythema, diminish the thickness of the affected skin areas, and control the transepidermal
water loss [87]. The proposed NPs are suitable in delivering glucocorticoid-related drugs, in order to
decrease the fibrotic and inflammatory patterns, and to improve the elasticity of the connective tissues
in AD patients.
Transfersomes loading tacrolimus were compared with liposomes containing the same drug
and with the ointment marketed product (Protopic®). Transfersomes achieved higher retention of
tacrolimus than the other two [88].
Chitosan nanoparticles have been proposed for the delivery of nicotinamide and tacrolimus for
the treatment of AD [89], and their in vitro and in vivo permeation compared to a commercial ointment
(Protopic). The authors reported that the enhanced permeation effect of NPs through, and into, the
skin, contributed to increased amounts of tacrolimus in the skin. This approach has been proposed as
adjuvant therapy and moderate anti–AD effects.
An in vivo study in mice has described the topical application of guar gum NPs, which were
shown to reduce the cellular infiltration and epidermal thickness in oxazolone-induced AD [1]. The NPs
used in this study were derived from Cyamopsis tetragonoloba, which contains galactomannan, known
to increase the cellular uptake of macrophages mediated by their over-expressed mannose receptors.
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NPs made of chitosan were loaded with tacrolimus and further covered with hyaluronic acid [90].
The results from in vitro studies demonstrated that tacrolimus was kept both in epidermal and
dermal layers—proof of successful targeting—decreasing the overall intensity of erythema and
the transepidermal water loss. Particles covered with hyaluronic acid showed other promising
effects in the skin, as anti-dermatitis, which point to a possible successful system in targeting
immunomodulatory drugs.
Lipid NPs, loaded with tacrolimus, improved penetration across the skin, reaching the more
profound layers (with resident dendritic cells) [91]. The comparison between tacrolimus-loaded lipid
NPs and the ointment Protopic® revealed that the former had boosted bioavailability. Systemic
distribution of the drug was not observable, which constitutes a favourable factor.
A system consisting of flexible vesicles loaded with levocetirizine was assessed on its safety and
dermatologic ability to pass through the skin. The results confirmed the criteria of skin safety and
demonstrated that this system was able to penetrate/permeate across the skin and had higher retention
capacity in comparison to liposomes, due to the flexible features of the vesicles [92].
A study also employing the antihistamine levocetirizine, but formulated in elastic vesicles and
topically applied, showed an increased flexibility of the membranes of these vesicles, a critical feature
allowing the vesicles to pass through pores in the human body with sizes smaller than their dimensions.
The increased permeability of the drug, along with reduced erythema intensity and itching, were also
reported [93]. A schematic representation of nanoparticles used as potential strategies for the treatment
of atopic dermatitis is shown in Figure 3.
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11. Toxicological Concerns and Legal Issues
The main concern when using NPs as drug delivery systems is their cytotoxicity profile. NPs
interact with cells at different levels and may also induce an immunological response. Neutral or
negatively charged NPs are better tolerated than their positively charged counterparts [94]. Negatively
charged NPs of mean diameter below 200 nm showed a dramatic reduction in the discharge of
pro-inflammatory factors when concomitantly administered with 1-fluoro-2,4-dinitrobenzene (DNFB),
which is a Th1-cell sensitizer [95]. This mechanistic is explained by the inhibition of the degranulation
process of mast cells with a later enrolment of other types of immune cells. Other studies showed
typical immune responses when free DNFB was applied. Keratinocytes demonstrated an enhanced
production of cytokines as IL-1β and IL-18, responsible for triggering and expanding the activation
and degranulation of mast cells, with further release of histamine [94,96].
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The overall toxicity triggered by NPs can be assessed at distinct levels, namely, at molecular,
cellular, tissue, and organ level [54], as drug pathway differ if it is loaded within NPs or if it is free. The
smaller the NPs, the higher the ability to penetrate across the skin, allowing improved access to systemic
circulation, and therefore, to several organs and body tissues. The decrease of the mean particle size
may increase their reactivity with consequent harmful effects in vivo. The phenomenon of protein
aggregation surrounding the NPs surface is commonly observed [97]. NPs may trigger cell toxicity
through the generation of reactive oxygen species (ROS) by Fenton’s reaction. ROS are damaging and
lead to the loss of lysosome membrane integrity with later release of enzymatic hydrolytic machinery,
iron cations, and protons. These latter lead to mitochondrial dysfunction, protein aggregation, and
increased cellular oxidative stress [98,99]. Toxicological assays are, therefore, of utmost importance in
forecasting the likely toxicity of given NPs [98].
The legislation governing nanotechnology-derived medicines does not need to have extremely
detailed guidelines. Nevertheless, it is vital that the medicines are in conformity with the current rules
of safety to avoid any toxicological risks.
12. Conclusions
Overall, AD is primarily characterized by its chronic pattern along with important modifications
in the quality of life of patients and caretakers. The first-line treatments aim to reduce the pruritus,
associated inflammation, and to rebuild the integrity of the skin using drugs as topical corticosteroids
and/or topical calcineurin inhibitors. Despite this, chronic treatment using these compounds, and in
particular, topical corticosteroids, leads to skin shrinkage due to the inhibition of collagen synthesis.
In children, there is an associated risk of systemic distribution of these drugs, which is a result of
their barely developed skin, and subsequent harmful adverse side effects. Topical treatments with
nanoparticles avoid the absorption of considerable amounts of drug due to the limited capacity of
the former to penetrate the stratum corneum. Since AD modifies skin homeostasis, novel treatments,
focusing on the restoration of the normal function of the skin, intended to regulate and stop the
associated inflammation, are urgently required. In the last years, the daily usage of NPs grew massively,
mostly due to their remarkable properties. Among these uses include; the ability to be targeted to a
tissue or cells; the possibility to achieve an easier control of the drug release profile and the ability
to penetrate/permeate the skin, allowing the NPs to be in contact with the most profound layers of
it, decrease in skin irritation; and the overall adverse effects of the drug, thereby, improving patient
acquiescence to therapeutics. The challenge concerns the therapeutic agents and medicines available.
Approaches using NPs-derived systems in the therapy of AD are being exploited. There are many
advantages as the effectiveness of the medicine and its lower cost, the reduced administered doses
(as NPs are very efficient in the targeted delivery which allows the medicine to be administered with
longer intervals) increasing patients’ compliance, and reducing the overall toxicity as the drug is
retained in the skin and is targeted. Novel nano-engineered systems are currently being tested in AD
models, and are promising for the future treatment of this disease. NPs may be capable in reducing the
adverse side effects of currently available treatments of AD. Despite this, it is of utmost importance to
guarantee the safety and efficacy of NPs, allowing the generation of potentially marketable products.
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